NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...

Indaptus Therapeutics (INDP) provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of ...

Real-Time Innovations (RTI) is the infrastructure software company for smart-world systems. RTI Connext ® is the world's leading software framework for intelligent distributed systems. Uniquely, ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles ...

A high throughput screen of >30,000 diverse repressor domains from across the tree of life identifies repressor domains with unique structures that underpin enhanced epigenetic effector domain ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

NEW YORK - Indaptus Therapeutics, Inc. (NASDAQ:INDP), a biotech firm specializing in novel treatments for cancer and viral infections, has announced the approval of patents in China, Japan, and Israel ...